期刊文献+

施慧达治疗原发性高血压128例临床观察 被引量:2

CLINICAL EFFECT OF LEVAMLODIPINEBESLATE TREATING 128 CASES OF PRIMARY HYPERTENSION
下载PDF
导出
摘要 目的探讨施慧达对中、老年收缩期高血压的降压效果及安全性。方法128例原发性高血压患病停用其它降压药3天,停用其它的降压药3天,并行心脏B超、心电图、常规生化检查(包括血、尿常规、肝功、肾功、电解质、血脂、血糖),作为原始资料,以备进行对比。用法用量:治疗高血压和心绞痛的初始剂量为2·5mg,一日1次;根据患者的临床反应,可将剂量增加,最大可增至5·0mg,一日1次。治疗3个月对统计数据进行统计学处理。结果Ⅰ级有效为71例,Ⅱ级有效为33例,Ⅲ级有效4例。治疗前后血压值有显著差异(p<0.05),特别是收缩压下降明显。Ⅰ、Ⅱ、Ⅲ级治疗前分别有14例、11例、7例心电图ST段和T波明显异常者,治疗后均有不同程度改善。血、尿常规、肝、肾功能、血糖、血脂、电解质均无显著变化。有2例在服药过程中出现面色潮红,1例出现踝部水肿症状,不能耐受而改用其它降压药,其它均无不良反应。结论施慧达是治疗老年人高血压的有效药物,尤其是Ⅰ、Ⅱ级收缩期高血压老年人,能够持久平稳地降压,避免心脑血管并发症的发生,对老年患者具有保护作用,且不良反应少,使用安全。
作者 胡靳乐 杨静
出处 《现代医院》 2008年第2期46-47,共2页 Modern Hospitals
  • 相关文献

参考文献5

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2张喜田.可生成水合物的左旋氨氯地平盐和其水合物及其制剂.中国专利申请号01140027.7[P].
  • 3VAN DER KROGT J P, BRAND R. Dawson EC: Amlodipine versus extended - release felodipine in general practice: a randomized,parallel- group study in patients with mild - moderate hypertension [ J ]. Curt Ther Res, 1996,57 : 145 - 158.
  • 4DAYI Hu, XIULI ZHAO, XIN HE, et al. Effect of "Drug Holiday" an blood pressure control: a randomized double - blind comparatlve trial of amlodipine versus felodipine extended release in Chinese patients with mild to moderate essential hypertension[ J]. Heart Drug,2001,1:77 - 82.
  • 5胡大一,赵秀丽,何欣,陶大宁,王寿岚,卫国靖,邱志勇,刘寅,李万益,李兆霞,张桂兰.氨氯地平与非洛地平缓释剂治疗原发性轻、中度高血压的随机、双盲平行对照研究[J].中国医药导刊,2000,2(4):1-5. 被引量:30

二级参考文献10

  • 1White WB,Morganroth J.Usefulness of ambulatory monitoring of blood pressure in assessing antihypertensive therapy[].The American Journal of Cardiology.1989
  • 2James R.The effect of amlodipine on ambulatory blood pressure in bypertensive patients[].The American Journal of Cardiology.1994
  • 3Abernethy DR.The pharmacokinetic profile of amlodipine[].American Heart Journal.1989
  • 4Saltiel E,Ellrodt AG,Monk SP,et al.Felodipine.A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension[].Drugs.1988
  • 5Hedner T,Elmfeldt D,Dahlof C,et al.Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in the arterial hypertension[].Drugs.1987
  • 6Smilde JG.A comparation of Amlodipine and Felodipine extended release in the treatment of hypertension at steady state and after two missed doses[].Current Therapeutic Research.1997
  • 7Mroczek WJ,Bunis JF,Allendy KS.A double- blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients[].Journal of Cardiovascular Pharmacology.1988
  • 8Koenig W.Efficacy and tolerability of felodipine and amlodipine in the treatment of mild hypertension[].Drug Investigation.1993
  • 9Ueda S,Meredith P,Howie CA,et al.A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects[].British Journal of Clinical Pharmacology.1993
  • 10Rudd P.Partial compliance: implications for clinical practice[].Journal of Cardiovascular Pharmacology.1993

共引文献2647

同被引文献16

  • 1刘艳,金玮,姜正文,张奎星,盛海辉,金璘,沈亚云,黄薇,于金德.血管紧张素原基因的六种单核苷酸多态与原发性高血压的相关性[J].中华医学遗传学杂志,2004,21(2):116-119. 被引量:16
  • 2Yanai K, Saito T, Hirota K, et al. Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcription initiation site affects its transcriptional activity [J]. J Bio Chem, 1997,27 (48): 30558-30562.
  • 3Tiago A D, Samani N J, Candy G P, et al. Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension [J]. Circulation, 2002, 106(12) : 1483-1487.
  • 4Wu S J, Chiang F T, Chen W J, et al. Three single- nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: single locus genotype vs. haplotype analysis [J]. Physiol Genomics, 2004,17 (2) :79- 86.
  • 5Brand-Herrmann S M, Kopke K, Reichenberger F, et al. Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives [J]. J Hypertens, 2004, 22(7) : 1289-1297.
  • 6Dickson M E, Sigmund C D. Genetic basis of hypertension: revisiting angiotensinogen [ J ]. Hypertension, 2006,48 ( 1 ) : 14-20.
  • 7LiuYW, QinWJ, HouSQ, et al. A-6G variant of the angiotensinogen gene and essential hypertension in Han, Tibetan and Yi populations [J]. Hypertens Res, 2001,24(2): 159-163.
  • 8Markovic D, Tang X, Guruju M, et al. Association of angiotensinogen gene polymorphisms with essential hypertension in African-Americans and Caucasians [J]. Hum Hered, 2005, 60(2) :89-96.
  • 9Hitgers K F, Delles C, Veelken R, et al. Angiotensinogen core promoter variants and non-modulating hypertension [J]. Hypertension, 2001,38(6) : 1250-1254.
  • 10Province M A, Boerwinkle E, Chakravarti A, et al. Lack of association of the angiotensinogen-6 polymorphism with blood pressure levels in the comprehensive NHLBI Family Blood Pressure Program [J]. J Hypertens, 2000,18(7) :867-876.

引证文献2

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部